Archives

Byondis appoints Christoph Korpus as Chief Executive Officer

Byondis

Byondis BV, an independent biopharmaceutical company developing innovative targeted medicines for cancer patients, announced the appointment of Christoph Korpus, PhD, MBA, as Chief Executive Officer (CEO), effective immediately. Christoph has served as the company’s Chief Business Officer (CBO) since January 2025. He succeeds Jacques Lemmens, PhD, the founder and former CEO of Byondis, who will remain on the Board of Directors as Chairman.

In his new role as CEO, Christoph will drive the further development of research and development activities for Byondis’ novel antibody-drug conjugate (ADC) technology platforms. These platforms, which combine proprietary, novel payloads with state-of-the-art linker and conjugation technologies as well as conditional activation, include Byondis’ cytotoxic antifolate linker-drug platform, ByonGuard™ masking technology for conditional activation, and the immunostimulatory ByonBoost™ linker-drug platform. Each of these technology platforms has generated several groundbreaking and promising drug candidates. Thanks to its fully integrated discovery, development, and manufacturing capabilities, Byondis can independently complete all essential development steps for its leading candidates. Byondis is open to partnerships regarding its pipeline assets and to licensing its technology for joint development projects.

Christoph brings more than 15 years of experience in the biopharmaceutical industry, ranging from oncology research and development and digital innovation to global business development and licensing. Prior to joining Byondis, Christoph was Director of Global Business Development and Licensing Oncology at Merck KGaA, where he led partner strategies and negotiation teams for numerous oncology transactions. During his time at Merck, Christoph drove company-wide innovation by managing global sales and development alliances across various therapeutic areas.

Also Read: Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Jacques Lemmens, PhD, Chairman of the Board of Directors of Byondis, said: “Since Christoph joined us as CBO last year, he has been instrumental in Byondis’ strategic realignment into a focused, fully integrated biotech company with multiple proprietary ADC technology platforms and deep expertise in clinical research and manufacturing. His extensive experience in global corporate development and strategic partnerships, combined with a profound understanding of how our platforms can address the significant unmet medical need in oncology, makes him ideally suited to lead Byondis through its next phase of growth. I am confident that under his leadership, the company will further advance its innovative pipeline to deliver groundbreaking solutions to patients as quickly as possible.”

Christoph Korpus, PhD, MBA, the newly appointed Chief Executive Officer, said: “It is a great honor for me to take the helm of this company, especially now that the path to maximizing the value of our decades of ADC expertise is so clear. My primary focus is now on delivering on our strategic vision, nurturing partnerships that drive our growth, and working with our talented team to develop innovative ADC therapies that overcome the serious limitations of current and future treatments, making a significant difference for cancer patients. Under Jacques’ leadership, Byondis has built extensive capabilities in both ADC discovery and development, as well as GMP-compliant manufacturing. My goal is to fully leverage these strengths as we further maximize the potential of our platforms and advance our differentiated programs.”

Christoph holds a PhD from Ludwig-Maximilians-Universität München and the University of Connecticut, as well as an MBA from the Kellogg School of Management at Northwestern University and WHU – Otto Beisheim School of Management.

Source: BusinessWire